Premium
Phospholipase A 2 ‐dependent effects of the venom from the new guinean small‐eyed snake Micropechis ikaheka
Author(s) -
Kuruppu Sanjaya,
Isbister Geoffrey K.,
Hodgson Wayne C.
Publication year - 2005
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20334
Subject(s) - myotoxin , venom , antivenom , snake venom , pharmacology , guinea pig , biology , chemistry , medicine , biochemistry , endocrinology
The New Guinean small‐eyed snake ( Micropechis ikaheka ) is a cause of life‐threatening envenoming. Previous studies on M. ikaheka venom have indicated the presence of neurotoxins as well as myotoxins. This study examined the in vitro myotoxic effects of M. ikaheka venom and the efficacy of a polyvalent antivenom in neutralizing these effects. Venom (50 μg/ml) produced a slowly developing contracture and inhibition of direct twitches of the chick biventer cervicis nerve–muscle preparation in the presence of tubocurarine (10 μM). Myotoxicity was confirmed by subsequent histological examination of tissues. This myotoxicity was prevented by the prior addition of polyvalent snake antivenom (30 U/ml). However, the addition of antivenom (30 U/ml) 1 h after venom administration failed to reverse or prevent the further inhibition of direct twitches. In addition, venom (1–10 μg/ml) produced concentration‐dependent contractions of the guinea‐pig isolated ileum. These effects were dependent on phospholipase A 2 (PLA 2 ) activity of the venom as evidenced by the ability of the PLA 2 inhibitor 4‐bromophenacyl bromide (4‐BPB; 1.8 mM) to prevent this activity. This study indicates that M. ikaheka venom causes significant myotoxicity and that polyvalent snake antivenom may be a potential treatment for the myotoxic effects in patients envenomed by this species. Muscle Nerve, 2005